Activities of β-Lactams and Macrolides against *Helicobacter pylori*

IBRAHIM J. HASSAN,†* ROGER M. STARK,† JOHN GREENMAN,‡ AND MICHAEL R. MILLAR†

Pathology and Microbiology Department, University of Bristol, Bristol BS2 8HW,† and Faculty of Applied Sciences, University of the West of England, Frenchay, Bristol BS16 1QY,‡ United Kingdom

Received 17 August 1998/Returned for modification 10 December 1998/Accepted 24 March 1999

A continuous-culture system (chemostat) was used to study the activities of β-lactam antimicrobial agents, clarithromycin, and 14-0H-clarithromycin against slowly growing *Helicobacter pylori* NCTC 11637. *H. pylori* was grown to steady state before exposure to these antimicrobial agents at ×8 the MIC. The bactericidal actions of combinations of amoxicillin and clarithromycin were also studied. Viable counts (numbers of CFU per milliliter) were determined at 2-h intervals for 12 h and at 20 h after the addition of antibiotics. The effects of pH changes (6.5 to 7.4) on the activities of amoxicillin, clarithromycin, and the combination of these against *H. pylori* NCTC 11637 were also studied. Viable counts following exposure to amoxicillin, cefixime, ceftazidime, cefuroxime, cefotaxime, azlocillin, and piperacillin at 20 h showed bacteriostatic activity. Imipenem, meropenem, amoxicillin, clarithromycin, and 14-0H-clarithromycin reduced the viable counts by 3 log₁₀ CFU/ml (≥99.9% killing). Imipenem was the most rapidly bactericidal against *H. pylori* NCTC 11637. Results of the pH experiments showed that amoxicillin was bacteriostatic at pHs 6.5 to 7.4. Clarithromycin was bactericidal at pH 7.0 to 7.4 but was bacteriostatic at pH 6.5. The combination of amoxicillin and clarithromycin was bactericidal at pHs 6.5 and 7.0. A batch culture (flask system) was also used to investigate 12 strains of *H. pylori* for their susceptibilities to β-lactams, clarithromycin, and/or 14-0H-clarithromycin in order to determine whether results from the chemostat model can be reproduced with batch cultures. Results of the chemostat time-kill kinetic study were reproducible in our batch culture flask system. The role of carbenemems in the eradication of *H. pylori* should be investigated.

Over the past 15 years *Helicobacter pylori* has emerged as an important human pathogen associated with gastroduodenal pathology (9, 10, 38). It is the principal cause of type B antral gastritis and contributes to the etiology of peptic ulcer disease. *Helicobacter pylori* is susceptible to a wide range of antimicrobial agents (5, 16, 23). Al-though *H. pylori* is susceptible to a wide range of antimicrobial agents in vitro (29), this does not translate into in vivo efficacy, and eradication requires the use of combinations of antimicrobial agents (5, 16, 23).

We report on a comparison of the activities of β-lactam antibiotics and macrolides against slowly growing *H. pylori* strains in continuous and batch cultures. The effect of pH on the activities of amoxicillin and clarithromycin alone and in combination against *H. pylori* NCTC 11637 in the chemostat was also studied. The investigations of bactericidal agents active against *H. pylori* in vitro may contribute to better strategies for eradication therapy. These may also help to determine if the in vivo success of clinical treatment regimens can be predicted by a chemostat model.

**MATERIALS AND METHODS**

**Bacterial strains.** *H. pylori* NCTC 11637 was used in all the chemostat experiments and, together with 11 other strains (NCTC 11916 and 10 clinical isolates) obtained at endoscopy from patients at the Bristol Royal Infirmary, Bristol, United Kingdom, between 1993 and 1996, was used for the batch culture kinetic study.

**Growth conditions.** *H. pylori* NCTC 11637 was used in all the chemostat experiments and, together with 11 other strains (NCTC 11916 and 10 clinical isolates) obtained at endoscopy from patients at the Bristol Royal Infirmary, Bristol, United Kingdom, between 1993 and 1996, was used for the batch culture kinetic study.

**Antimicrobial agents.** The antimicrobial agents used in this study were ampicillin and amoxicillin (Beecham Laboratories, Betchworth, United Kingdom), imipenem (MSD Ltd., Hoddesdon, Herts, England), meropenem (ICI plc Macclesfield, Cheshire, England), piperacillin and cefixime (Lederle Laboratories, Gosport, Hants, England), azlocillin (Bayer Ltd., Berkshire, United Kingdom), ceftazidime and cefuroxime (Glaxo, Middlesex, England), cefotaxime (Roussel Laboratories Ltd., Uxbridge, England), and clarithromycin (Abbott Laboratories, Queenuh, United Kingdom). Each antimicrobial agent was prepared prior to use in accordance with the manufacturer’s instructions, with a stock solution of known potency being produced.

**Establishment of cultures in the chemostat.** The chemostat used for the experiments was an LH 500 series direct-drive fermentor with control modules for temperature, pH, gas flow, and stir rate (Inceltech UK Ltd., Reading, Berks, United Kingdom). It consists of a culture vessel fitted with an overflow device to maintain a constant volume (15, 41). The method used in the present study for establishment of a stable continuous culture of slowly growing *H. pylori* was a modification of that described previously (32); namely, *H. pylori* was harvested from Columbia agar plates, suspended in 7 ml of sterile brucella broth that had been warmed to 37°C, and inoculated aseptically into 700 ml of modified brucella broth in the growth vessel of the chemostat. A microaerophilic gas mixture consisting of O₂, CO₂, and N₂ at 5:10:85 (in percent [vol/vol]), respectively, was filtered through a 0.2-μm-pore-size filter and was sparged at a rate of 300 ml/min through the chemostat vessel. The stir rate was maintained at 700 rpm, while the pot volume at this stir rate was 700 ml. Sterile growth medium from the medium reservoir was fed by a peristaltic pump into the culture vessel at a rate of 700 ml/24 h to give a dilution rate of 0.04 h⁻¹. The maximum specific growth rate (μmax) of *H. pylori* NCTC 11637 under these conditions was 0.052 at pH 6.5, 0.132 at pH 7.0, 0.212 at pH 7.2, and 0.180 at pH 7.4. The incubation
temperature was 37°C. The medium flow was started when the broth became visibly turbid and the chemostat culture was then allowed to stabilize over the next 5 to 6 days, permitting the establishment of a steady state between bacterial growth and bacterial washout, at which point the killing-kinetic experiments were started. Once the pH for the experiment was set, it was maintained by the automatic addition of acid (1 M HNO₃) or alkali (1 M NaOH) from the pH control unit. When the bacterial viable count became stable the oxygen saturation was approximately 5%. The purity of the chemostat culture during the experiments was monitored by daily Gram staining and culturing of samples at 37°C under aerobic, anaerobic, and microaerophilic conditions.

Establishment of batch cultures (flask system). Cultures of H. pylori were established with a set of 250-ml conical flasks each containing 98 ml of sterile brucella broth and 1 ml of fetal calf serum into which 1 ml of a standardized H. pylori (10⁶ CFU/ml) culture was inoculated. The flasks were placed inside an orbital incubator at 37°C and were agitated at 150 rpm, and a filtered microaerophilic gas mixture was bubbled through the cultures at a rate of 150 ml/min. During the deceleration phase of growth (i.e., after about 16 h of incubation), when the cells were growing at a reduced rate compared to the rate at which they grew while they were in the midexponential phase, the test antibiotics were added at a concentration of 8 × the MIC. Sixteen hours was chosen after calculation of the physiologic “growth cycle” showed deceleration of the growth rate at this time point under these experimental conditions.

Determination of bactericidal activity. Each antimicrobial agent was added in a pulse directly into the broth within the culture vessel to give a final concentration of 8 × the MIC at the start of the experiments. After incubation of the organism-antibiotic mixture, a sample of 500 μl was removed from the chemostat vessel (or flasks) for determination of viable counts (numbers of CFU per milliliter) as described previously (31). The sample was serially diluted (1:10) in warm phosphate-buffered saline, and 20-μl volumes from each dilution were spread in triplicate onto Columbia blood agar plates. The inoculated plates were incubated at 37°C under microaerophilic conditions for 72 h before the colonies were counted. Only the organisms on plates yielding mean viable counts of at least 500 CFU/ml were counted, and the results were recorded. Samples were collected for viable count determinations immediately preceding the addition of

<table>
<thead>
<tr>
<th>Strain</th>
<th>Imipenem</th>
<th>Meropenem</th>
<th>Ampicillin</th>
<th>Amoxicillin</th>
<th>Clarithromycin</th>
<th>14-OH-clarithromycin</th>
<th>Cefixime</th>
<th>Cefuroxime</th>
<th>Cefotaxime</th>
<th>Piperacillin</th>
<th>Azlocillin</th>
<th>Ceftazidime</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCTC 11637</td>
<td>0.06</td>
<td>0.06</td>
<td>0.25</td>
<td>0.12</td>
<td>0.06</td>
<td>0.06</td>
<td>0.50</td>
<td>0.50</td>
<td>1.00</td>
<td>0.25</td>
<td>0.25</td>
<td>2.00</td>
</tr>
<tr>
<td>NCTC 11916</td>
<td>0.06</td>
<td>0.12</td>
<td>0.25</td>
<td>0.12</td>
<td>0.03</td>
<td>NT</td>
<td>0.50</td>
<td>0.50</td>
<td>1.00</td>
<td>0.50</td>
<td>0.50</td>
<td>1.00</td>
</tr>
<tr>
<td>18868</td>
<td>0.12</td>
<td>0.25</td>
<td>0.25</td>
<td>0.12</td>
<td>0.12</td>
<td>NT</td>
<td>0.25</td>
<td>1.00</td>
<td>1.00</td>
<td>0.50</td>
<td>0.50</td>
<td>2.00</td>
</tr>
<tr>
<td>2985</td>
<td>0.06</td>
<td>0.25</td>
<td>0.12</td>
<td>0.12</td>
<td>0.06</td>
<td>NT</td>
<td>0.25</td>
<td>1.00</td>
<td>1.00</td>
<td>0.50</td>
<td>0.50</td>
<td>2.00</td>
</tr>
<tr>
<td>KAL</td>
<td>0.12</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
<td>0.06</td>
<td>NT</td>
<td>0.25</td>
<td>1.00</td>
<td>1.00</td>
<td>0.50</td>
<td>0.50</td>
<td>2.00</td>
</tr>
</tbody>
</table>

* NT, not tested.

![FIG. 1. Killing kinetics of antimicrobial agents (at 8 × MIC) at pH 7.0 in chemostat cultures for H. pylori NCTC 11637. □, imipenem; ●, meropenem; ▼, Amoxicillin; ▲, clarithromycin; •, 14-OH-clarithromycin; ×, washout; →, time of antibiotic addition.](http://aac.asm.org/)

![TABLE 1. MICs of antimicrobial agents for H. pylori strains](http://aac.asm.org/)
antimicrobial agents to the chemostat vessel (or flasks) and at 2, 4, 6, 8, 10, 12, and 20 h. The presence of antimicrobial agents in the flasks (or chemostat) was monitored by a microbiological agar well diffusion assay as described previously (2). From the mean viable counts, killing and viability curves were determined, and from these curves the bactericidal activity of each agent was calculated. The bacterial inoculum at the start of the experiments was $8.0 \pm 0.2 \log_{10}$ CFU/ml.

Each experiment was repeated three times.

RESULTS

MICs. The MICs of the antimicrobial agents for all the H. pylori isolates tested are presented in Table 1.

Chemostat. Figure 1 is a graphic representation of the chemostat killing curves for H. pylori NCTC 11637 and shows the activities of those agents that produce a fall in bacterial count of at least $3 \log_{10}$ CFU/ml (≥99.9% killing) relative to that expected by washout of nondividing cells at 20 h. These bactericidal agents include amoxicillin, meropenem, imipenem, clarithromycin, and 14-OH-clarithromycin. Imipenem was the most rapidly bactericidal, with a decrease in the bacterial count of $4 \log_{10}$ CFU/ml at 8 h. From 10 h onward after the addition of imipenem it was not possible to detect H. pylori by determination of viable counts from the chemostat broth, which became markedly less turbid. The bacteriostatic agents included ampicillin, cefixime, cefuroxime, cefotaxime, and ceftazidime, which gave decreases in bacterial count of <1.5 $\log_{10}$ CFU/ml, while azlocillin and piperacillin produced decreases of 1.5 $\log_{10}$ CFU/ml (data not shown).

Effect of pH on activities of antimicrobial agents. (i) Amoxicillin. Figure 2 shows the results of the effect of pH 6.5, 7.0, 7.2, and 7.4 on the activity of amoxicillin against H. pylori NCTC 11637. Amoxicillin was bactericidal at all pH values (≥99.9% killing). It was most rapidly cidal at pHs 7.4 and 7.2 with a decrease of $3 \log_{10}$ CFU/ml at 10 h compared with a decrease of $3 \log_{10}$ at pHs 7.0 and 6.5 at 20 h. The pH optima for killing by amoxicillin were 7.2 and 7.4.

(ii) Clarithromycin. Figure 3 shows the results of the effect of pHs 6.5 to 7.4 on the activity of clarithromycin against H. pylori NCTC 11637. Clarithromycin was bactericidal at pHs 7.0 to 7.4 and achieved killing of at least $3 \log_{10}$ CFU/ml at 20 h (≥99.9% killing). It was, however, only bacteriostatic at pH 6.5 and caused a decrease in the bacterial count of $1 \log_{10}$ CFU/ml at 20 h.

(iii) Combination of amoxicillin and clarithromycin. Figure 4 shows the killing curves for the combined activity of clarithromycin and amoxicillin against H. pylori NCTC 11637 at pHs 6.5 and 7.0. At both pHs the combination was bactericidal from 8 h onward. There was also greater cidal activity for the combination compared to the activities of the antibiotics individually at the same pHs. The cidal activity of amoxicillin at pH 6.5 was comparable to that at pH 7.0 (Fig. 4).

Batch culture (flask system). Figure 5 shows the killing curves for H. pylori NCTC 11637 in a batch-culture system. Amoxicillin, meropenem, imipenem, and clarithromycin were all bactericidal. Imipenem was still the most bactericidal agent, with a decrease of $3.5 \log_{10}$ CFU/ml at 12 h, followed by meropenem, amoxicillin, and clarithromycin, with a decrease of $3 \log_{10}$ CFU/ml at 20 h. 14-OH-clarithromycin was only bacteriostatic and gave a fall of $2.5 \log_{10}$ CFU/ml. The other β-lactams were as bacteriostatic with the batch-culture system as with the chemostat (data not shown).

Other strains. For H. pylori NCTC 11916 and five clinical strains, imipenem was the most rapidly bactericidal agent, with a killing of at least $3 \log_{10}$ CFU/ml at 20 h, and was the only
agent that was bactericidal for two of the strains. For a further two strains (strains 3266 and AMMI) only imipenem and meropenem were bactericidal. For strain 18868 imipenem, amoxicillin, and clarithromycin were equally bactericidal at 20 h, while strain 2985 was equally killed at 20 h by imipenem, meropenem, and clarithromycin. For one strain (TIYO) clarithromycin was the only bactericidal agent, with the rest of the agents, including imipenem, remaining only bacteriostatic (Table 2).

**DISCUSSION**

We have compared the activities of 10 β-lactams, clarithromycin, and 14-OH-clarithromycin against slowly growing _H. pylori_ NCTC 11637 in both the chemostat and batch cultures (flask system). The chemostat, which can grow bacteria at the rate set by the experimenter, is a good model for killing-kinetic studies. It may provide results which are more predictive of the in vivo situation in which bacteria have a more prolonged doubling time compared to that under in vitro conditions (28). The chemostat has been used previously for killing-kinetic studies (8, 32). However, we are unaware of any comparison of this system for killing-kinetic studies with cheaper traditional batch-culture methods. We have compared the two systems for killing-kinetic studies and have shown similar trends in the activities of β-lactam antibiotics and clarithromycin against slowly growing _H. pylori_ NCTC 11637. In both systems, imipenem, meropenem, amoxicillin, and clarithromycin were bactericidal, while the remaining antimicrobial agents were bacteriostatic. Imipenem was the most rapidly bactericidal agent, although it was bactericidal to a lesser degree in the batch culture than in the chemostat. Also, 14-OH-clarithromycin, which was bactericidal in the chemostat, was bacteriostatic only in the batch culture (flask system).

The current search for agents with improved anti-_H. pylori_ activities continues. No single agent give adequate eradication, and compliance is a problem with current multidrug regimens for the treatment of _H. pylori_ infection (42). Clarithromycin has achieved the highest reported eradication rates of any mono-therapy (34) and, like amoxicillin, has become an established part of combination therapy for _H. pylori_ infection (35). The fact that imipenem and meropenem were bactericidal against most strains may be of interest in view of the current development of novel oral carbapenems (3, 40). Our results suggest that carbapenems may have a role in the therapy of _H. pylori_-associated disease. In vitro and gut pharmacokinetic studies of the newer oral carbapenems would need to be performed. Imipenem, for example, is widely distributed in body fluids and secretions including gastric juice, in which suprainhibitory concentrations have been found following intravenous administration (14, 39). A recent pilot study of imipenem monotherapy for 48 h has achieved good clearance but has failed to eradicate _H. pylori_ from the gut (39). The short duration of therapy in this study makes comparison with longer-course regimens difficult. There is current interest in the use of intravenous antibiotics for the management of bleeding peptic ulcers in patients who are _H. pylori_ positive. There is evidence to support the view that eradication of _H. pylori_ from this group of patients prevents recurrence of the bleeding episode (1, 19, 26).

The study of the effect of pH changes on the activities of antimicrobial agents against microorganisms had been report-
ed previously for batch cultures (4, 17, 20). Changes in pH can affect the activities of antimicrobial agents as well as the expression of bacterial target sites. Our chemostat data showed that amoxicillin had pH optima for killing of *H. pylori* NCTC 11637 at 7.2 and 7.4. This is in agreement with previous reports (6, 37). This was not surprising since amoxicillin is an amphoteric agent which is less ionized at acidic pH. Clarithromycin was bactericidal at all pHs except pH 6.5. The activities of macrolides have been known to be decreased at acidic pH, but the degree to which they are affected varies between members of this group of agents (12). Clarithromycin has been reported to be bactericidal at acidic pH (13, 22), while others have reported a loss of activity of clarithromycin at acidic pH (6), a result similar to that of the present study.

The omeprazole-based combination therapy with clarithromycin and amoxicillin is now a regimen of choice for the treatment of *H. pylori* infection in Europe (27). The results of the present combination study show that at both pH 6.5 and pH 7.0, there was bactericidal activity which was greater than the activities of the individual agents at the same pH. Omeprazole facilitates secretion of antibiotics into the mucosa and increases tissue bioavailability (21). Previous studies have not demonstrated synergy between various combinations of omeprazole, amoxicillin, and clarithromycin in vitro (6, 30, 37).

In conclusion, the greater activity of imipenem compared with those of other β-lactams and clarithromycin should prompt further studies and the search for oral carbapenems with potential anti-*H. pylori* activity.

### REFERENCES


